A Novel Floating In Situ Chewable Gel System for Curcumin Delivery with Potential Application in Obesity Management
Saravoot Pumjan1, Rachanida Praparatana2, Ousanee Issarachot3
1Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hatyai 90112, Songkhla, Thailand.
Gels (Basel, Switzerland)
|April 27, 2026
Summary
A novel chewable gel enhances curcumin
Area of Science:
- Pharmacology
- Materials Science
- Biotechnology
Background:
- Curcumin has anti-obesity and anti-inflammatory effects but poor solubility and bioavailability limit its use.
- Developing effective delivery systems is crucial for enhancing curcumin's therapeutic potential.
Purpose of the Study:
- To develop a transformable chewable gel for improved oral delivery of curcumin.
- To create a gastroretentive drug delivery system for enhanced anti-obesity and anti-inflammatory effects.
Main Methods:
- Curcumin solid dispersions (CUR-SDs) were prepared using Eudragit® EPO and solvent evaporation.
- Optimized CUR-SDs were incorporated into chewable gels with sodium alginate, κ-carrageenan, and calcium carbonate.
- Formulations were characterized for solubility, dissolution, mechanical strength, floating behavior, and drug release kinetics.
Main Results:
- The optimized CUR-SD (1:3) significantly improved curcumin solubility and dissolution in acidic conditions.
- The chewable gels formed buoyant matrices with sustained drug release up to 8 hours.
- Formulation F7 demonstrated optimal texture, floating, and controlled-release properties, with potent anti-inflammatory and anti-adipogenic activity.
Conclusions:
- The developed in situ gelling chewable platform effectively enhances curcumin's oral bioavailability and therapeutic efficacy.
- This gastroretentive strategy shows promise for treating obesity and related inflammatory conditions.
More Related Videos
Related Concept Videos
Oral Drug Delivery Systems: Continuous-Release Systems
297
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
297
Oral Drug Delivery Systems: Introduction
271
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
271
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
437
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
437
Oral Drug Delivery Systems: Delayed-Release Systems
206
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
206
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
Drug Dosing: Obese Patients
364
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
364


